A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.
Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
DRUG: Cannabidiol Oral Solution [Epidiolex]
Change in the most problematic behavior Numerical Rating Score (NRS) score within the TAND-SQ, Baseline, Week 13, Week 26, Week 52|Change in Tuberous Sclerosis Complex Associated Neuropsychiatric Disorders Self-report, Quantified Checklist (TAND-SQ) score, Baseline, Week 13, Week 26, Week 52|Change in Aberrant Behavior Checklist (ABC) score, Baseline, Week 13, Week 26, Week 52|Change in Child Behavior Checklist (CBCL) score, Baseline, Week 26, Week 52|Change in Adult Behavior Checklist (ABCL) score, Baseline, Week 26, Week 52|Change in Adult Self-Report (ASR) score, Baseline, Week 26, Week 52|Change in Patient-Reported Outcomes Measurement Information System (PROMIS) domains score, Baseline, Week 26, Week 52|Change in sleep characteristics using the Children's Sleep Habits Questionnaire (CSHQ), Baseline, Week 26|Change in sleep characteristics using the Pittsburgh Sleep Quality Index (PSQI), Baseline, Week 26|Change in executive function using Behavior Rating Inventory of Executive Function (BRIEF), Baseline, Week 26|Change in caregiver-reported assessment of Quality of Life (QOL) using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM), Baseline, Week 26|Change in caregiver-reported assessment of family functioning using Pediatric Quality of Life Survey Family Impact Module (PedsQL FIM), Baseline, Week 26|Change in assessment of QOL using Pediatric Quality of Life Inventory (PedsQL), Baseline, Week 26|Change in caregiver impression of overall severity of symptoms (behavior and seizure control) using the Caregiver Global Impression of Severity (CareGI-S), Baseline, Week 4, Week 13, Week 26, Week 52|Change in participant impression of overall severity of symptoms (behavior and seizure control) using the Patient Global Impression of Severity (PGI-S), Baseline, Week 4, Week 13, Week 26, Week 52|Change in clinician impression of overall severity of symptoms (behavior and seizure control) using the Clinician Global Impression of Severity (CGI-S), Baseline, Week 4, Week 13, Week 26, Week 52|Retention Rate, Retention rate is the number of participants continuing with CBD-OS treatment over total accrued participants, Baseline, Week 13, Week 26, Week 52|Number of participants considered treatment responders, Treatment responders will be reported as those with a 25%, 50%, 75% and 100% reduction in seizure frequency from baseline, Baseline, Week 4, Week 13, Week 26, Week 52|Change in number of seizure-free days, Baseline, Week 4, Week 13, Week 26, Week 52|Number of participants experiencing a worsening, no change, or improvement in seizure frequency, Number of participants who experience a change in seizure frequency from baseline defined as:

1. worsening (\>25%)
2. no change (-25 to + 25%)
3. improvement (-25% to -50%, ≥-50% to -75%, ≥-75%), Baseline, Week 4, Week 13, Week 26, Week 52|Change in ideation score per the Columbia-Suicide Severity Rating Scale (C-SSRS), Baseline, Week 4, Week 13, Week 26, Week 52|Change in number of suicide attempts per the C-SSRS, Baseline, Week 4, Week 13, Week 26, Week 52|Change in ideation score per the Children's C-SSRS, Baseline, Week 4, Week 13, Week 26, Week 52|Change in number of suicide attempts per the Children's C-SSRS, Baseline, Week 4, Week 13, Week 26, Week 52|Number of participant inpatient hospitalizations due to epilepsy, Up to Week 52|Number of withdrawals due to Treatment Emergent Adverse Events (TEAEs), Up to Week 52
The purpose of this study is to investigate behavioral and other co-occurring outcomes with EPID(I/Y)OLEX as an add-on therapy in participants aged 1 to 65 years with tuberous sclerosis complex (TSC) who experience seizures.